United States

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

18 Apr 2018
Change (% chg)

$0.31 (+4.19%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Alpine Immune Sciences qtrly earnings per share ‍$0.18​
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Alpine Immune Sciences Inc ::Alpine Immune Sciences reports corporate update and third quarter 2017 financial results.Q3 revenue $100,000 versus $700,000.Alpine Immune Sciences Inc - ‍company expects to have cash to fund operations into 2020​.Alpine Immune Sciences Inc qtrly earnings per share ‍$0.18​.  Full Article

Frazier Life Sciences reports 15.8 pct stake in Alpine Immune Sciences
Monday, 31 Jul 2017 06:09am EDT 

July 31 (Reuters) - Alpine Immune Sciences Inc :Frazier Life Sciences reports 15.8 percent stake in Alpine Immune Sciences as of July 24, 2017 - SEC filing.  Full Article

Alpine Immune Sciences completes merger with Nivalis Therapeutics
Tuesday, 25 Jul 2017 06:30am EDT 

July 25 (Reuters) - Alpine Immune Sciences:Alpine Immune Sciences Inc completes merger with Nivalis Therapeutics Inc.Nivalis Therapeutics Inc - ‍upon completion of merger and financing, Alpine will have approximately $90 million in cash and cash equivalents​.Nivalis Therapeutics Inc - ‍combined company changed its name to Alpine Immune Sciences​.  Full Article

Nivalis Therapeutics stockholders approve reverse stock split
Thursday, 20 Jul 2017 06:00am EDT 

July 20 (Reuters) - Nivalis Therapeutics Inc :Nivalis Therapeutics - stockholders approved on July 19 reverse stock split of co's common stock, at ratio of 1 new share for every 4 shares outstanding.Nivalis Therapeutics Inc - stockholders approved all of merger-related proposals in special meeting on July 19.  Full Article

Nivalis Therapeutics enters into merger agreement with Alpine Immune Sciences
Monday, 1 May 2017 04:01pm EDT 

May 1 (Reuters) - Nivalis Therapeutics Inc ::Nivalis Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.57.Nivalis Therapeutics -increased loss for quarter due to $3.5 million in restructuring charges and a $2.0 million increase in stock-based compensation expenses.Nivalis Therapeutics -after a review and negotiation with alpine immune sciences, board decided to approve and enter definitive merger agreement with Alpine.Nivalis -Frazier Healthcare Partners, Alpine Bioventures, Orbimed Advisors, will invest combined additional $17 million into alpine immune sciences prior to close.Nivalis -following merger, Alpine shareholders will own about 74 percent of combined co and nivalis shareholders will own about 26 percent of combined co.Nivalis -Mitchell Gold., alpine's executive chairman and ceo , will become chairman and ceo of combined company.Nivalis Therapeutics Inc says following merger, board of directors of combined company will expand to seven seats.  Full Article

Nivalis Therapeutics reports termination fee amount
Tuesday, 18 Apr 2017 05:22pm EDT 

April 18 (Reuters) - Nivalis Therapeutics Inc ::Nivalis Therapeutics-on termination of agreement under specified circumstances, Alpine or co may be required to pay other party termination fee of $2.5 million.Nivalis Therapeutics-upon termination of merger agreement,Alpine or co in some circumstances to reimburse other party's expenses to maximum $1 million-sec filing.  Full Article

Nivalis Therapeutics and Alpine Immune Sciences Inc agree to combine
Tuesday, 18 Apr 2017 04:05pm EDT 

April 18 (Reuters) - Nivalis Therapeutics Inc : :Nivalis Therapeutics Inc and Alpine Immune Sciences Inc. Agree to combine.Nivalis therapeutics inc - merger will result in a combined company.Nivalis Therapeutics Inc - Alpine will merge with a wholly-owned subsidiary of nivalis in an all-stock transaction.Nivalis Therapeutics-Frazier Healthcare Partners, Alpine Bioventures, Orbimed Advisors to invest additional $17 million into Alpine Immune Sciences.Nivalis Therapeutics Inc - following merger, current alpine shareholders will own approximately 74 percent of combined company.Nivalis Therapeutics Inc - transaction has been approved by board of directors of both companies.Nivalis Therapeutics Inc - upon closing of transaction, name of combined company will become Alpine Immune Sciences Inc.  Full Article

Nivalis Therapeutics reports Q4 loss per share of $0.50
Monday, 13 Feb 2017 04:05pm EST 

Nivalis Therapeutics Inc : Nivalis Therapeutics reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.50 .Q4 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Nivalis therapeutics announces corporate restructuring
Thursday, 12 Jan 2017 04:10pm EST 

Nivalis Therapeutics Inc : Nivalis Therapeutics announces corporate restructuring . Nivalis Therapeutics Inc says intends to complete a reduction in force affecting 25 employees . Nivalis Therapeutics Inc - Board of directors has approved a restructuring plan as part of company's initiative to explore strategic alternatives . Says estimates that it will incur cash severance costs of approximately $3 million . Nivalis Therapeutics - Co estimates it will incur cash severance costs of approximately $3 million, which are expected to be paid during first half of 2017 . Nivalis Therapeutics Inc says Congleton will be stepping down from his role as president and chief executive officer effective January 15, 2017 . Says reduction in force is intended to preserve company's cash while it assesses various strategic alternatives . Nivalis Therapeutics - Co currently projects that it will have approximately $45-$47 million of net cash available for potential strategic transaction . Nivalis Therapeutics - Reduction in workforce includes Jon Congleton, president & CEO, and David Rodman, M.D., chief medical officer .Board has appointed Michael Carruthers, co's chief financial officer, as interim president, effective Jan 15, 2017.  Full Article

Nivalis Q2 loss per share $0.55
Monday, 1 Aug 2016 04:05pm EDT 

Nivalis Therapeutics Inc : Q2 loss per share $0.55 . Nivalis therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article